AU2012241805B2 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
AU2012241805B2
AU2012241805B2 AU2012241805A AU2012241805A AU2012241805B2 AU 2012241805 B2 AU2012241805 B2 AU 2012241805B2 AU 2012241805 A AU2012241805 A AU 2012241805A AU 2012241805 A AU2012241805 A AU 2012241805A AU 2012241805 B2 AU2012241805 B2 AU 2012241805B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
oxytocin
seq
nothing
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012241805A
Other languages
English (en)
Other versions
AU2012241805A1 (en
Inventor
Anders Carlsson
Kerstin Uvnas-Moberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PeP-Tonic Medical AB
Original Assignee
PeP-Tonic Medical AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PeP-Tonic Medical AB filed Critical PeP-Tonic Medical AB
Publication of AU2012241805A1 publication Critical patent/AU2012241805A1/en
Application granted granted Critical
Publication of AU2012241805B2 publication Critical patent/AU2012241805B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2012241805A 2011-04-14 2012-04-13 Pharmaceutical composition Ceased AU2012241805B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161475471P 2011-04-14 2011-04-14
SE1150324-0 2011-04-14
SE1150324A SE536091C2 (sv) 2011-04-14 2011-04-14 Farmaceutisk komposition innehållande oxytocin eller fragment eller varianter därav och åtminstone en icke-jonisk cellulosaeter
US61/475,471 2011-04-14
PCT/EP2012/056813 WO2012140216A1 (en) 2011-04-14 2012-04-13 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
AU2012241805A1 AU2012241805A1 (en) 2013-10-24
AU2012241805B2 true AU2012241805B2 (en) 2016-08-11

Family

ID=47008851

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012241805A Ceased AU2012241805B2 (en) 2011-04-14 2012-04-13 Pharmaceutical composition

Country Status (17)

Country Link
US (1) US9034821B2 (enExample)
EP (1) EP2696882B1 (enExample)
JP (1) JP5993442B2 (enExample)
KR (1) KR101940341B1 (enExample)
CN (1) CN103596582B (enExample)
AU (1) AU2012241805B2 (enExample)
BR (1) BR112013026153A2 (enExample)
CA (1) CA2832664C (enExample)
DK (1) DK2696882T3 (enExample)
ES (1) ES2535521T3 (enExample)
IL (1) IL228821A (enExample)
PL (1) PL2696882T3 (enExample)
RU (1) RU2605288C2 (enExample)
SE (1) SE536091C2 (enExample)
SG (1) SG194074A1 (enExample)
WO (1) WO2012140216A1 (enExample)
ZA (1) ZA201308157B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2908840A1 (en) * 2012-10-12 2015-08-26 Peptonic Medical AB Novel use of a composition comprising oxytocin
JP7030517B2 (ja) 2015-01-07 2022-03-07 トライジェミナ， インコーポレイテッド マグネシウム含有オキシトシン製剤および使用の方法
US9925233B2 (en) * 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
BR112018005811A2 (pt) * 2015-10-30 2018-10-16 Teijin Pharma Limited composição farmacêutica para administração na mucosa nasal
CN115814055A (zh) 2016-04-12 2023-03-21 三叉神经股份公司 含镁催产素制剂和应用方法
SE1750680A1 (en) * 2017-05-30 2018-12-01 Peptonic Medical Ab Composition for treating or preventing climacteric disorders
EP3852723B1 (en) * 2018-09-20 2025-11-05 ACADIA Pharmaceuticals Inc. Stable intranasal formulations of carbetocin
CN110169377B (zh) * 2019-06-27 2021-09-14 浙江海洋大学 黄姑鱼的人工催产受精方法
SE547797C2 (en) 2023-09-25 2025-11-25 Letavis Ab Stimulation of plant germination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042452A1 (en) * 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism
WO2010118888A1 (en) * 2009-04-17 2010-10-21 Merz Pharma Gmbh & Co. Kgaa Formulation for stabilizing proteins, which is free of mammalian excipients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3076797A (en) 1957-07-22 1963-02-05 Roussel Uclaf Process of producing oxytocin and intermediates obtained thereby
US2938991A (en) 1957-10-01 1960-05-31 Candace Inc Electric mattress pad
JPS61126014A (ja) * 1984-11-22 1986-06-13 Teijin Ltd 経鼻投与用水性液剤
SE466134B (sv) 1990-11-22 1992-01-07 Kabi Pharmacia Ab Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
GB9326354D0 (en) 1993-12-23 1994-02-23 British Aerospace Methods and apparatus for the testing,monitoring and improvement of manufacturing process effectiveness
SE9400918L (sv) * 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
US5833647A (en) * 1995-10-10 1998-11-10 The Penn State Research Foundation Hydrogels or lipogels with enhanced mass transfer for transdermal drug delivery
CA2247191C (en) 1996-02-27 2005-01-04 Teijin Limited Powdery composition for nasal administration
SE9701162D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9701161D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
SE9701184D0 (sv) 1997-04-01 1997-04-01 Karolinska Innovations Ab Substanser för att åstadkomma preferens och skapa acceptans
SE9803272D0 (sv) * 1998-09-25 1998-09-25 Kerstin Uvnaes Moberg A drug for cell regeneration
SE0001440D0 (sv) * 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
SE0100684D0 (sv) * 2001-02-28 2001-02-28 Kerstin Uvnaes Moberg New subject-matter
SE0102184D0 (sv) 2001-06-19 2001-06-19 Uvnaes Moberg Kerstin New subject-matter
SE0102910D0 (sv) * 2001-08-31 2001-08-31 Moberg Kerstin Uvnaes New use
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US7884076B2 (en) * 2003-11-06 2011-02-08 The Trustees Of Columbia University In The City Of New York Multipeptide regimen for the treatment of autistic spectrum, behavioral, emotional and visceral inflammation/autoimmune disorders
JP5324091B2 (ja) * 2004-06-24 2013-10-23 アイデックス ラボラトリーズ，インコーポレイティド 薬物送達のための医薬組成物及びそれを使用する症状の治療又は予防法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042452A1 (en) * 2006-09-29 2008-04-10 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions comprising oxytocin or an analog for the treatment of autism
WO2010118888A1 (en) * 2009-04-17 2010-10-21 Merz Pharma Gmbh & Co. Kgaa Formulation for stabilizing proteins, which is free of mammalian excipients

Also Published As

Publication number Publication date
CN103596582A (zh) 2014-02-19
KR20140019830A (ko) 2014-02-17
RU2605288C2 (ru) 2016-12-20
CN103596582B (zh) 2016-03-16
ZA201308157B (en) 2015-01-28
CA2832664C (en) 2020-03-24
SE536091C2 (sv) 2013-04-30
HK1189158A1 (en) 2014-05-30
SE1150324A1 (sv) 2012-10-15
ES2535521T3 (es) 2015-05-12
SG194074A1 (en) 2013-11-29
DK2696882T3 (en) 2015-04-27
JP2014515747A (ja) 2014-07-03
US9034821B2 (en) 2015-05-19
AU2012241805A1 (en) 2013-10-24
BR112013026153A2 (pt) 2019-09-17
IL228821A0 (en) 2013-12-31
RU2013147739A (ru) 2015-05-20
EP2696882A1 (en) 2014-02-19
SE536091E5 (enExample) 2015-04-21
CA2832664A1 (en) 2012-10-18
EP2696882B1 (en) 2015-03-04
JP5993442B2 (ja) 2016-09-14
IL228821A (en) 2016-08-31
WO2012140216A1 (en) 2012-10-18
US20140171369A1 (en) 2014-06-19
KR101940341B1 (ko) 2019-01-18
PL2696882T3 (pl) 2015-08-31

Similar Documents

Publication Publication Date Title
AU2012241805B2 (en) Pharmaceutical composition
Martin et al. Injectable peptide hydrogels for controlled-release of opioids
CN109562063A (zh) 包含人胰高血糖素和末端接枝的共聚氨基酸的可注射水溶液形式的组合物
Martin et al. Injectable peptide-based hydrogel formulations for the extended in vivo release of opioids
JP2001233787A (ja) 小・中サイズのペプチド含有薬学的組成物
EP2571488B2 (en) Pharmaceutical composition of ibuprofen for injection
JP6800372B2 (ja) 持続型パルミチン酸結合ＧｎＲＨ誘導体及びこれを含む薬剤学的組成物
TWI745313B (zh) 鼻黏膜投與用醫藥組成物
CN112423775B (zh) 替维瑞克-tfa组合物
EP2908840A1 (en) Novel use of a composition comprising oxytocin
US20170232059A1 (en) Composition comprising oxytocin
WO2018133009A1 (zh) 一种富马酸沃诺拉赞组合物及其制备方法
US20150164913A1 (en) Testosterone gel compositions and related methods
TW201440783A (zh) 含有米卡芬淨或其鹽的醫藥組成物
Cilurzo et al. A novel oromucosal prolonged release mucoadhesive suspension by one step spray coagulation method
CN106456706B (zh) 稳定化的去氨加压素
KR20090130001A (ko) 코피 방지용 조성물
JP2005529864A (ja) （２−ヒドロキシメチルインダニル−４−オキシ）フェニル４，４，４−トリフルオロブタン−１−スルホネートの水性製剤
JPH10298102A (ja) カルシトニン注射液
HK40003871A (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
HK40004511A (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired